Sanofi, Cipla enters into exclusive distribution partnership to expand reach of CNS portfolio in India

This partnership entails that Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium®, a brand in the anti-epileptic medication category.

While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.

Rodolfo Hrosz, Managing Director, Sanofi India Limited, said, “Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve the lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India.”

Achin Gupta, Chief Executive Officer – One India Business, Cipla Limited, said, “Enhancing access to high quality treatments is central to our purpose of ‘Caring for Life’. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central Nervous System is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients.”

This is in line with Sanofi India’s continued focus on accelerating its innovation pipeline into India, across multiple therapeutic areas including diabetes, transplants, rare diseases, consumer healthcare and vaccines.